176 related articles for article (PubMed ID: 17449210)
1. Cross-over assessment of serum bactericidal activity of moxifloxacin and levofloxacin versus penicillin-susceptible and penicillin-resistant Streptococcus pneumoniae in healthy volunteers.
Hart D; Weinstein MP
Diagn Microbiol Infect Dis; 2007 Jul; 58(3):375-8. PubMed ID: 17449210
[TBL] [Abstract][Full Text] [Related]
2. Serum bactericidal activities of moxifloxacin and levofloxacin against aerobic and anaerobic intra-abdominal pathogens.
Stein GE; Schooley S; Tyrrell KL; Citron DM; Nicolau DP; Goldstein EJ
Anaerobe; 2008 Feb; 14(1):8-12. PubMed ID: 17983770
[TBL] [Abstract][Full Text] [Related]
3. Evaluation of bacterial kill when modelling the bronchopulmonary pharmacokinetic profile of moxifloxacin and levofloxacin against parC-containing isolates of Streptococcus pneumoniae.
Deryke CA; Du X; Nicolau DP
J Antimicrob Chemother; 2006 Sep; 58(3):601-9. PubMed ID: 16857688
[TBL] [Abstract][Full Text] [Related]
4. In vitro pharmacodynamics of moxifloxacin versus levofloxacin against 4 strains of Streptococcus pneumoniae: 1 wild type, 2 first-step parC mutants, and 1 pump mutant.
Schafer J; Hovde LB; Simonson D; Rotschafer JC
Diagn Microbiol Infect Dis; 2008 Feb; 60(2):155-61. PubMed ID: 17910998
[TBL] [Abstract][Full Text] [Related]
5. Pharmacodynamics of moxifloxacin and levofloxacin against Streptococcus pneumoniae, Staphylococcus aureus, Klebsiella pneumoniae and Escherichia coli: simulation of human plasma concentrations after intravenous dosage in an in vitro kinetic model.
Odenholt I; Cars O
J Antimicrob Chemother; 2006 Nov; 58(5):960-5. PubMed ID: 16936293
[TBL] [Abstract][Full Text] [Related]
6. Bactericidal activity of moxifloxacin against multidrug-resistant Streptoccocus pneumoniae at clinically achievable serum and epithelial lining fluid concentrations compared with three other antimicrobials.
Cafini F; Alou L; Sevillano D; Valero E; Prieto J;
Int J Antimicrob Agents; 2004 Oct; 24(4):334-8. PubMed ID: 15380257
[TBL] [Abstract][Full Text] [Related]
7. Streptococcus pneumoniae response to repeated moxifloxacin or levofloxacin exposure in a rabbit tissue cage model.
Xuan D; Zhong M; Mattoes H; Bui KQ; McNabb J; Nicolau DP; Quintiliani R; Nightingale CH
Antimicrob Agents Chemother; 2001 Mar; 45(3):794-9. PubMed ID: 11181363
[TBL] [Abstract][Full Text] [Related]
8. A pharmacodynamic approach to antimicrobial activity in serum and epithelial lining fluid against in vivo-selected Streptococcus pneumoniae mutants and association with clinical failure in pneumonia.
Alou L; Giménez MJ; Sevillano D; Aguilar L; Cafini F; Echeverría O; Pérez-Trallero E; Prieto J
J Antimicrob Chemother; 2006 Aug; 58(2):349-58. PubMed ID: 16782744
[TBL] [Abstract][Full Text] [Related]
9. Pharmacokinetics of moxifloxacin in non-inflamed cerebrospinal fluid of humans: implication for a bactericidal effect.
Kanellakopoulou K; Pagoulatou A; Stroumpoulis K; Vafiadou M; Kranidioti H; Giamarellou H; Giamarellos-Bourboulis EJ
J Antimicrob Chemother; 2008 Jun; 61(6):1328-31. PubMed ID: 18353805
[TBL] [Abstract][Full Text] [Related]
10. Comparative antibacterial effects of moxifloxacin and levofloxacin on Streptococcus pneumoniae strains with defined mechanisms of resistance: impact of bacterial inoculum.
Bowker KE; Garvey MI; Noel AR; Tomaselli SG; Macgowan AP
J Antimicrob Chemother; 2013 May; 68(5):1130-8. PubMed ID: 23361641
[TBL] [Abstract][Full Text] [Related]
11. Correlation between in vitro and in vivo activity of levofloxacin and moxifloxacin against pneumococcal strains with different susceptibilities to fluoroquinolones.
Huelves L; Sevillano D; Martínez-Marín C; López-Casla MT; Gracia M; Alou L; del Carmen Ponte M; Prieto J; Soriano F;
Int J Antimicrob Agents; 2006 Apr; 27(4):294-9. PubMed ID: 16527462
[TBL] [Abstract][Full Text] [Related]
12. Pharmacodynamics of moxifloxacin and levofloxacin simulating human serum and lung concentrations.
Schubert S; Dalhoff A; Stass H; Ullmann U
Infection; 2005 Dec; 33 Suppl 2():15-21. PubMed ID: 16518707
[TBL] [Abstract][Full Text] [Related]
13. Susceptibility patterns of bacterial isolates from hospitalised patients with respiratory tract infections (MOXIAKTIV Study).
Jacobs E; Dalhoff A; Korfmann G
Int J Antimicrob Agents; 2009 Jan; 33(1):52-7. PubMed ID: 18835763
[TBL] [Abstract][Full Text] [Related]
14. In vitro interactions of LytA, the major pneumococcal autolysin, with two bacteriophage lytic enzymes (Cpl-1 and Pal), cefotaxime and moxifloxacin against antibiotic-susceptible and -resistant Streptococcus pneumoniae strains.
Rodríguez-Cerrato V; García P; Del Prado G; García E; Gracia M; Huelves L; Ponte C; López R; Soriano F
J Antimicrob Chemother; 2007 Nov; 60(5):1159-62. PubMed ID: 17827138
[TBL] [Abstract][Full Text] [Related]
15. High doses of levofloxacin vs moxifloxacin against staphylococcal experimental foreign-body infection: the effect of higher MIC-related pharmacokinetic parameters on efficacy.
Murillo O; Pachón ME; Euba G; Verdaguer R; Tubau F; Cabellos C; Cabo J; Gudiol F; Ariza J
J Infect; 2009 Mar; 58(3):220-6. PubMed ID: 19217166
[TBL] [Abstract][Full Text] [Related]
16. AUC(0-t)/MIC is a continuous index of fluoroquinolone exposure and predictive of antibacterial response for Streptococcus pneumoniae in an in vitro infection model.
Zelenitsky SA; Ariano RE; Iacovides H; Sun S; Harding GK
J Antimicrob Chemother; 2003 Apr; 51(4):905-11. PubMed ID: 12654762
[TBL] [Abstract][Full Text] [Related]
17. Pharmacodynamics of moxifloxacin and levofloxacin against Staphylococcus aureus and Staphylococcus epidermidis in an in vitro pharmacodynamic model.
Lister PD
Clin Infect Dis; 2001 Mar; 32 Suppl 1():S33-8. PubMed ID: 11249827
[TBL] [Abstract][Full Text] [Related]
18. Efficacy of moxifloxacin for treatment of penicillin-, macrolide- and multidrug-resistant Streptococcus pneumoniae in community-acquired pneumonia.
Fogarty C; Torres A; Choudhri S; Haverstock D; Herrington J; Ambler J
Int J Clin Pract; 2005 Nov; 59(11):1253-9. PubMed ID: 16236076
[TBL] [Abstract][Full Text] [Related]
19. Emergence of high-level fluoroquinolone resistance in emm6 Streptococcus pyogenes and in vitro resistance selection with ciprofloxacin, levofloxacin and moxifloxacin.
Malhotra-Kumar S; Van Heirstraeten L; Lammens C; Chapelle S; Goossens H
J Antimicrob Chemother; 2009 May; 63(5):886-94. PubMed ID: 19279051
[TBL] [Abstract][Full Text] [Related]
20. Emergence of resistant Streptococcus pneumoniae in an in vitro dynamic model that simulates moxifloxacin concentrations inside and outside the mutant selection window: related changes in susceptibility, resistance frequency and bacterial killing.
Zinner SH; Lubenko IY; Gilbert D; Simmons K; Zhao X; Drlica K; Firsov AA
J Antimicrob Chemother; 2003 Oct; 52(4):616-22. PubMed ID: 12951352
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
